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Background: Little is known about the signiﬁcance of haemoglobin genotype in dengue fever severity. This study
was undertaken to determine the case fatality ratio and the impact of genotype in patientswith sickle cell disease
and conﬁrmed dengue fever.
Methods: This retrospective analysis included 40 patients with conﬁrmed dengue and sickle cell disease, during
the study period (2010–2012).
Findings: There was a signiﬁcantly higher case fatality ratio, 12.5% among patients with either haemoglobin SC
disease or homozygous SS disease when compared to that of the general population 0.41% (p b 0.0001). The
unadjusted odds of dying among thosewith haemoglobin SC disease comparedwith the groupwith homozygous
SS disease was OR = 4.4 (95% CI 0.6 to 31.7). The predictors of mortality independent of sickle cell disease
genotype were haemoglobin concentration at presentation OR = 0.57 (95% CI, 0.35 to 0.94) and the change in
haemoglobin concentration from steady state OR = 0.59 (95% CI, 0.37 to 0.94). Adjusting for haemoglobin
concentration at presentation increased the risk of death for the SC genotype relative to SS genotype OR =
13.4 (95% CI 1.1 to 160.3).
Interpretation: The risk of fatal dengue may be higher among patients with a relatively mild genotype
(haemoglobin SC).
© 2015 The Authors. Published by Elsevier B.V. This is an open access article under the CC BY-NC-ND license
(http://creativecommons.org/licenses/by-nc-nd/4.0/).1. Introduction
Sickle-cell disease (SCD) is considered a major global public health
problem (Serjeant, 2014). There are approximately 250,000 births
annually (Hannemann et al., 2011). Africa, bears the highest burden of
the disease (Makani et al., 2013). However many cases occur in theies with a high burden of Sickle
fever. The two most common
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. This is an open access article underUnited States of America, the Caribbean, and Northern Europe
(Hannemann et al., 2011). In Jamaica the β-globin chain abnormalities
βS and βC occur with gene frequencies of 0.055 and 0.019 respectively
(Serjeant, 1981). Differences in the characteristics of haemoglobin C
and S have been reported, including distinctly more noticeable K+ loss
and dehydration in haemoglobin SC red cells and this contributes to
differences in the phenotypic manifestations between haemoglobin SC
disease (HbSC) disease and homozygous haemoglobin SS (HbSS) dis-
ease (Hannemann et al., 2011). However whether there are phenotypic
differences in response to dengue fever between the genotypes is un-
clear. In Jamaica, the Sickle Cell Unit (SCU) is the only comprehensive
care facility that provides care for SCDwithmore than 5000 individuals
registered at the facility.
Many countries with a high SCD burden are also known to have out-
breaks of dengue fever (DF) which is a mosquito borne, viral illness
(Brown et al., 2009). In fact, like SCD, dengue fever is also amajor public
health concern (Limonta et al., 2009) and is endemic in at least 100
countries in Asia, the Paciﬁc, the Americas, Africa, and the Caribbean.
It is said that more than one-third of the world's population live in
these high risk areas. In the tropics and subtropics, DF is a leadingthe CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
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World Health Organization (WHO) estimates that 50 to 100 million
dengue infections occur yearly, including 500,000 cases of dengue
hemorrhagic fever (DHF) and 22,000 deaths annually, mostly among
children and during the last 50 years, the incidence has increased 30-
fold (World Health Organization, 2014).
Indeed, there have been widespread epidemics of DF in Caribbean
countries including Cuba and Jamaica. The two most recent outbreaks
in Jamaica were in 2010 and 2012, where 3202 and 5903 suspected
cases were reported, respectively (National Surveillance Unit, Ministry
of Health, Jamaica). In Jamaica, DF is a class 1 reportable disease
(Ministry of Health Kingston Jamaica, 2012).
According to Sickle Cell Unit clinic guidelines, DF is suspected in per-
sonswith SCD if the patient presentswith a fever and two ormore of the
following symptoms: headache, retro-orbital pain, myalgia, arthralgia
or rash (Asnani et al., 2008). Patients were either treated as outpatients
or admitted to hospital depending on their clinical condition. During
epidemics, individual patients suspected of having DF are not always
speciﬁcally tested but in keeping with Ministry of Health reporting
guidelines, are designated as likely cases based on clinical criteria.
This study was undertaken to determine the case fatality ratio and
the signiﬁcance of genotype (HbSC and Hb SS) in patients with sickle
cell disease and dengue fever.2. Materials and Methods
2.1. Study Design
After approval by the University of the West Indies Ethics Commit-
tee, a retrospective review of charts of consecutive patients suspected
to have had DF during the period January 1, 2010 to December 31,
2012 was carried out. The above dates included 2 dengue fever
epidemics that occurred in 2010 and 2012. The privacy rights of patients
included in this study were strictly observed.
Persons were eligible to be included in the study if they were
registered patients at the SCU with a diagnosis of HbSS or HbSC and
had clinical features suggestive of DF (Asnani et al., 2008).Fig. 1. Flow chart of study participants.2.2. Diagnosis of DF
Patientswith HbSS disease, or HbSC seen at the SCUwhohad clinical
ﬁndings consistent with DF and dengue serology positive for dengue
viral antigen (NS1Ag) and or dengue-speciﬁc immunoglobulin M
(IgM) were classiﬁed as conﬁrmed DF while, those with both Ag and
dengue speciﬁc IgM negative were classiﬁed as unlikely DF. Suspected
cases were classiﬁed as possible DF if there were no available results
or if the results available were equivocal.
The IgM Elisa kit used was the dengue fever virus Capture DxSelect
(Focus Diagnostics, Cypress, PA, USA) (World Health Organization
Special Programme for Research and Training in Tropical Diseases
(TDR), 2009). This IgM assay detects dengue-speciﬁc immunoglobulin
M as early as day 3 to day 5 after the onset of an illness (World Health
Organization Special Programme for Research and Training in Tropical
Diseases (TDR), 2009; Peeling et al., 2010). The Dengue NS1 antigen
(SDBIOLINE Dengue DUO NS Ag, Standard Diagnostics) is detectable
up to nine days (Wang and Sekaran, 2010) after the onset of illness.
This is a lateral ﬂow (immunochromatographic) assay. All serological
investigations for DF, haemoglobin and other laboratory assays were
performed on the day of presentation which ranged from 1 to 10 days
(median 5 days) after the onset of illness.
Data from the Ministry of Health, Jamaica documented that the
epidemic which occurred in 2010 was attributable to serotype 2 and
that in 2012 was attributable to serotype 1 (National Surveillance
Unit, Ministry of Health, Jamaica).2.3. Deﬁnition of Steady State Blood Count
At the SCU this is deﬁned as the average of all complete blood counts
(CBCs) done after the age of four years at “well” or “routine visits” (that
is no ill health at or within 2 weeks of the visit). If patients are less than
four years, the last well CBC is used for comparison (Asnani et al., 2008).2.4. Death Ascertainment
Patients registered at the SCU who died were identiﬁed through an
existing surveillance system instituted by the Ministry of Health,
Jamaica and the SCU. Additional clinical information was obtained
from hospital records. The number of deaths among conﬁrmed cases
of DF in the general population was obtained from the National Surveil-
lance Unit, Ministry of Health, Jamaica.2.5. Statistical Analysis
The sample for analysis consisted of personswithHbSS or HbSCwith
laboratory conﬁrmed DF. Summary measures were expressed asmeans
with standard deviation or geometric meanswith 95% conﬁdence inter-
vals, as appropriate. Differences in mean values between groups were
tested using independent t-tests or Wilcoxon rank-sum test as appro-
priate. Highly skewed continuous variables were Napier transformed
prior to inferential testing by t-test. Associations between categorical
variables were tested using the chi-square statistic.
To assess the risk factors for death in the study sample, logistic re-
gressions were performed with the outcome being dead or alive and
the candidate predictors being genotype, haematological variables and
age. To reduce bias due low frequency of events and small sample size
a penalized likelihood estimation of the logistic regression was used
(Kosmidis and Firth, 2009). The Stata statistical software version 12
forWindows™ (College Station, TX77845)wasused for analysis. Signif-
icance was taken as p value of b0.05.3. Results
During the study period, January 1, 2010 to December 31, 2012, 111
patients with either HbSC or HbSS disease registered at the SCU were
suspected of havingDF. Of these 40 subjects (36.0%) had deﬁnitive sero-
logical evidence of current dengue fever (Conﬁrmed DF) and comprised
the analytical sample. Twenty-seven subjects (24.3%) had serology that
was not in keeping with dengue fever (Unlikely DF), while 44 subjects
(39.6%) had serological data that was either equivocal or unavailable
(Possible DF) (Fig. 1).
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Of the 40 personswith laboratory conﬁrmed DF 18 had HbSC and 22
had HbSS. There was no signiﬁcant difference in the gender distribution
between the groups or in mean age (HbSC 13.9 + 11.8 years vs HbSS
15.3 + 14.8 years). Similarly, there was no difference in the proportion
of patients hospitalized or the proportion receiving intensive unit care,
hydroxyurea and clinical symptoms between HbSC and HbSS groups.
However, in subjects with SC disease 63% (10 of 16 subjects) had a pal-
pable spleen on admission p b 0.01 and this was signiﬁcantly greater
than in proportion in HbSS 18% (3 of 17) (Table 1).3.2. Mortality
There were 7 conﬁrmed non sickle cell dengue related deaths in the
general population among 1716 laboratory conﬁrmed cases yielding a
case–fatality ratio of 0.41% or 4.1 per 1000. On the other hand there
were 5 deaths among 40 laboratory conﬁrmed cases with HbSS or
HbSC yielding a case–fatality ratio of 12.5% (125 per 1000). The case
fatality ratio was signiﬁcantly greater than in the general population
(p b 0.0001) Additionally, there were more deaths in SC group than
the SS genotype group resulting in higher case fatality ratio 222 per
1000 vs 45 per 1000 but the difference in proportionwas not statistical-
ly signiﬁcant (p = 0.09).
Within the HbSC group there were certain patterns observed. The
persons who died were generally older with lower haemoglobin on ad-
mission and with a greater fall in Hb from their documented steady
state. However, higher white cell counts were observed in this group
and as expected a greater proportion of them had intensive care admis-
sion. However these differences were not statistically signiﬁcant. There
was only one death in the HSS group who was a child (Table 1).
Logistic regressions were used to determine the major predictors of
mortality. The unadjusted odds of dying in SC compared with SS was
OR= 4.4 (95% CI 0.6 to 31.7). Adjusting for haemoglobin concentration
increased the risk of death for the SC genotype relative to SS genotype
OR = 13.4 (95% CI 1.1 to 160.3) (Table 2). In contrast adjusting for
change in haemoglobin concentration from steady state, did not signif-
icantly affect the odds of death in HbSC relative to HbSS. SimilarlyTable 1
Clinical characteristics of sample.
Variables HbSC
Survived
(N = 14)
Age, years (mean, SD) 11.0 (7.1)
Acute haemoglobin conc., g/dl 9.5 (1.3)
Steady state haemoglobin conc., g/dl 10.0 (1.0)
Change in haemoglobin conc.a, g/dl −0.5 (1.5)
Red cell count, ×1012 3.9 (0.4)
Acute platelet count, ×1012/l 170.1 (85.6)
Steady state platelets, ×1012/l (mean, SD) 273.1 (140.7)
Change in platelet countsa, ×1012/l (mean, SD) −96.1 (161.2)
Acute white cell countb, ×109/l (mean, SD) 6.2 (4.1 to 9.5)
Steady state white cell count, ×109/l (mean, SD) 8.8 (3.2)
Change in white cell counta, ×109/l (mean, SD) −0.4 (7.2)
Gender (M:F) 7:7
Hospital admission (Y:N) 11:3
Intensive care (Y:N) 1:13
Hydroxyurea use (Y:N) 0:0
Gastrointestinal symptoms (Y:N) 12:2
Presence of spleen, N = 33 (Y:N) 7:6
Rash (Y:N) 2:8
Abbreviations: conc= concentrations; values are counts ormeanswith SD. HbSC— sickle cell h
the average of all complete blood counts (CBCs) done after the age of four years at “well” or “rout
years, the last well CBC is used for comparison.
a Change is difference between values measured during DF and steady state.
b Values are geometric means with 95% conﬁdence interval.adjusting for acute white cell or platelet counts or change in white cell
or platelet counts from steady state did not signiﬁcantly affect the
odds of death for HbSC (data not shown).
The OR for haemoglobin concentration on presentation was 0.57
(95% CI, 0.35 to 0.94) and theOR for change in the haemoglobin concen-
trations from steady state was 0.59 (95% CI, 0.37 to 0.94). These were
predictors of mortality independent of SCD genotype even after
adjusting age (Table 2). Thus, among individuals with conﬁrmed den-
gue a higher haemoglobin concentration in the acute phase decreased
the risk of dying. That is, a higher haemoglobin concentration of 1 g/dl
in the acute phase decreased the probability of dying by 36%, adjusting
for genotype and 38% adjusting for genotype and age. While, when the
acute haemoglobin was compared to the steady state, it was found that
a decrease of 1 g/dl from the steady state increased the probability of
dying by 63% adjusting for genotype and 62% adjusting for genotype
and age.4. Discussion
In this study we sought to determine the mortality experience of
persons with HbSS and HbSC with laboratory conﬁrmed dengue, as
well as to ascertain whether there were differences in morbidity. Our
ﬁndings of a thirty fold increased mortality among persons with SCD,
is supported by previous reports mainly from Cuba, which have sug-
gested that SCD is a risk factor for severe DF. Bravo et al. (1987),
reporting on the 1981 Cuban epidemic, stated that chronic diseases
such as bronchial asthma, diabetes mellitus and sickle cell anaemia
(Hb SS disease) were risk factors for severe disease. Limonta et al.
(2009) reported two persons who died in the 2001–2002 Havana den-
gue epidemics, both with SCD. The genotypes of the affected persons
were however not stated. Moesker et al. (2013) reported two cases
from Curacao of fatal DF in persons with SCD (one case had Hb SC
disease, the other Hb SS disease).
The higher mortality in sickle cell disease compared to the general
population may be due to heighten inﬂammatory response in sickle
cell disease relative to subjects without sickle cell disease. For example
recent advances have shown that speciﬁc antibodies and T cells directly
inﬂuence a cytokine imbalance in dengue that eventually leads toHbSS
Died
(N = 4)
Survived
(N = 21)
Died
(N = 1)
23.7 (20.2) 15.8 (14.9) 4.3
6.2 (4.1) 6.6 (1.6) 3.7
10.3 (0.4) 7.9 (1.2) 7.9
−4.1 (4.4) −1.1 (1.3) −4.2
1.6 (0.8) 2.6 (1.0) 2.8
217.2 (149.0) 273.2 (154.6) 304.0
288.9 (73.3) 409.7 (131.7) 304
−55.6 (113.4) −127.1 (153) 0
15.6 (4. To 61.7) 14 (10.3 to 19.1) 11.6
10.5 (2.6) 11.3 (3.4) 12.0
6.4 (10.3) 7.6 (14.1) −0.4
3:1 9:12 0:1
4:0 16:5 1:0
3:1 1:20 1:0
0:0 2:19 0:1
3:1 14:7 0:1
3:0 3:14
1:3 1:11 0:1
aemoglobin C disease; HBSS— homozygous S sickle cell disease. Steady state— deﬁned as
ine visits” (that is no ill health at orwithin 2weeks of the visit). If patients are less than four
Table 2
Predictors of death in sample.
Model HbSC Acute haemoglobin
concentration
g/dl
Change in haemoglobin
concentrations
g/dl
Age
years
Unadjusted model 1 4.4,
0.6 to 31.7
– – –
Haematological adjusted models 2 13.4,
1.1 to 160.3
0.57,
0.35 to 0.94
– –
3 3.4,
0.4 to 28.9
0.59,
0.37 to 0.94
–
Age & haematological adjusted models 4 11.2,
0.94 to 133.4
0.60,
0.36 to 0.99
– 1.02,
0.95 to 1.1
5 2.9,
0.37 to 22.9
0.61,
0.38 to 0.97
1.01,
0.94 to 1.1
Values are odds ratio with 95% conﬁdence intervals. Model 2 bold signiﬁcance is the estimate of the effect (odds ratio), for the variable HbSC is signiﬁcant (pb 0.05).
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studies in patients with SCD have shown excessive inﬂammatory cyto-
kines in both steady-state and during a vaso-occlusive crisis and there-
fore the existence of ongoing inﬂammation (Musa et al., 2010). Taken
together these observationsmay indicate an ampliﬁed inﬂammatory re-
sponse in SCD during a dengue infection resulting in increased
morbidity and mortality.
Also, in this study, subjects within each genotype with lower
haemoglobin or greater fall in haemoglobin from steady state had
higher case fatality. This within group difference is probably reﬂective
of the extent of haemorrhage at presentation. Surprisingly, when geno-
types are compared, the HbSC genotype, which as a group, characteris-
tically have higher haemoglobin counts than HbSS, had a higher case
fatality. There are several possible pathophysiological mechanisms
that could be responsible for this observation.
Firstly, it may be that subjects with HbSC are more susceptible to
fatal dengue due to the increased susceptibility of the red blood cell
in HbSC to dehydration based on K+ loss (Hannemann et al., 2011).
This leads to a greater propensity for dense cell formation when
compared to HSS. These dense cells have an increased intracellular
haemoglobin concentration hence higher mean cell haemoglobin
concentration (MCHC). The higher MCHC causes both an increase
in HB S polymerization and also decreases the time to sickling
(Nagel et al., 2003). Perhaps the dengue virus either alters the
HbSC RBC rheology by triggering RBC dehydration or affects the en-
dothelial adhesivity resulting in a massive vascular leak syndrome
and intravascular dehydration. This in turn would result both in in-
travascular dehydration and massive sickling.
Another possible mechanism which could explain a higher mor-
bidity in HbSC disease is neo-angiogenesis. It has been reported
that neo-angiogenesis and retinopathy are more frequent in HbSC
patients (Banu et al., 2013). It is possible that blood vessels produced
by neo-angiogenesis aremore permeable in response to inﬂammato-
ry cytokines such as High mobility group box 1 (HMGB1) protein
which increases vascular permeability of endothelial cells in a dose
dependent manner in in-vitro experiments (Ong et al., 2012). The
HMGB protein is increased in dengue fever infection and sickle cell
vaso-occlusive crises (Xu et al., 2014) and is thought to play an im-
portant role in dengue shock syndrome (Ong et al., 2012). This
could contribute to a massive vascular leak syndrome, intravascular
dehydration and shock.
The study was limited by its retrospective design: inconsistencies in
the reporting methods of various laboratories led to some cases being
classiﬁed as possible DF rather than deﬁnitively conﬁrmed DF. Despite
this, four of ﬁve deaths with conﬁrmed DF occurred in SCD patients
with HbSC genotype. The authors were not able to determine primary
from secondary infections as methods such as IgG/IgM antibody ratios
were not available. However, based on past medical history recorded
in the patient notes, only 3 patients were documented as having DF
previously. They did not contribute to the deaths.5. Conclusion
In conclusion, DF was associated with a much higher morbidity in
patients with SCD. We therefore recommend that persons with SCD,
in particular Hb SC disease, who present with symptoms compatible
with DF during an epidemic, should be treated as high risk, and carefully
managed in an inpatient setting.Author Contributions
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